Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- Ask the CIO
- Connected Government
- Consolidating Mission-critical Systems
- Constituent Servicing
- The Data Privacy Imperative: Safeguarding Sensitive Data
- Eliminating the Pitfalls: Steps to Virtualization in Government
- Federal Executive Forum
- Federal Tech Talk
- Government Cloud Brokerage: Who, What, When, Where, Why?
- Government Mobility
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Mobile Device Management
- The Modern Federal Threat Landscape
- Moving to the Cloud. What's the best approach for me
- Navigating Tough Choices in Government Cloud Computing
- Satellite Communications: Acquiring SATCOM in Tight Times
- Transformative Technology: Desktop Virtualization in Government
- Understanding the Intersection of Customer Service and Security in the Cloud
Shows & Panels
This is an archive page for Bloomberg Government's Capital Impact radio show. Focusing on the business implications of government actions, Capital Impact explored the effects of government spending in core industries of defense, IT and technology, energy, finance, health care and transportation, and the appropriations process in Congress. For more information about Bloomberg Government, visit them online at BGov.com.
The future of health care cost savings
Thursday - 5/10/2012, 4:14am EDT
- Health Care Policy Analyst Christopher Flavelle examines the forces driving states to move more of their Medicaid populations into privately run insurance plans, and the impact it could have on state budgets, health insurance companies and care providers.
- The U.S. government is pouring billions of dollars into health care cost-savings research, but will that investment generate a return? Health Care Financial Analyst Brian Rye discusses controversial Comparative Effectiveness Research, whether the federal government is likely to find cost savings from it, and which industries stand to win or lose.
- And a key congressional committee eyes reauthorization of the FDA's user fee program for prescription drugs and medical devices. Rye and Congressional Analyst Loren Duggan examine the road to reauthorization and what's at stake for the drug and medical device industries.
||Loren Duggan is Bloomberg Government's chief legislative analyst. Before joining Bloomberg, he was editor of Congressional Quarterly's House Action Reports, providing summaries and analysis of legislation. He also contributed to CQ's legislative tracking services during his decade with the company. Loren holds a bachelor's degree in political science and psychology from American University.|
||Christopher Flavelle is a health care policy analyst for Bloomberg Government. Before Bloomberg, he examined the 2009 U.S. stimulus package for ProPublica, the investigative news group in New York. He holds a master's degree from Columbia University's School of International and Public Affairs and a bachelor's degree from McGill University.|
||Brian Rye is a health care financial analyst with Bloomberg Government. Before joining Bloomberg, he spent 12 years as an equity research analyst at SunTrust, Raymond James and Janney Montgomery Scott. In those capacities, he followed biotech, pharmaceutical and other health care companies. Rye also served as a senior business management analyst for Booz Allen Hamilton's civil health group. He received a bachelor's degree in economics from Vanderbilt University and holds the Chartered Financial Analyst designation.|
||Allen Scott (moderator) specializes in customer on boarding and training at Bloomberg Government. Allen previously worked at Arbitron, Inc. where he served in a variety of roles from customer service to sales operations manager. Prior to Arbitron, Allen worked in radio for several years in the Washington and Baltimore areas. Most recently he spent six years at 99.1 HFS as co-host and news director.|